Difference between revisions of "Neoadjuvant therapy"
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Neoadjuvant therapy''' is systemic treatment after diagnosis (on biopsy) prior to (definitive) local therapy.<ref name=pmid8242583>{{Cite journal | last1 = Trimble | first1 = EL. | last2 = Ungerleider | first2 = RS. | last3 = Abrams | first3 = JA. | last4 = Kaplan | first4 = RS. | last5 = Feigal | first5 = EG. | last6 = Smith | first6 = MA. | last7 = Carter | first7 = CL. | last8 = Friedman | first8 = MA. | title = Neoadjuvant therapy in cancer treatment. | journal = Cancer | volume = 72 | issue = 11 Suppl | pages = 3515-24 | month = Dec | year = 1993 | doi = | PMID = 8242583 }}</ref> | '''Neoadjuvant therapy''' is systemic treatment after diagnosis (on biopsy) prior to (definitive) local therapy.<ref name=pmid8242583>{{Cite journal | last1 = Trimble | first1 = EL. | last2 = Ungerleider | first2 = RS. | last3 = Abrams | first3 = JA. | last4 = Kaplan | first4 = RS. | last5 = Feigal | first5 = EG. | last6 = Smith | first6 = MA. | last7 = Carter | first7 = CL. | last8 = Friedman | first8 = MA. | title = Neoadjuvant therapy in cancer treatment. | journal = Cancer | volume = 72 | issue = 11 Suppl | pages = 3515-24 | month = Dec | year = 1993 | doi = | PMID = 8242583 }}</ref> | ||
''Post-neoadjuvant therapy'' | ''Post-neoadjuvant therapy'' and ''complete pathologic response'' redirect here. | ||
==See also== | ==See also== | ||
| Line 7: | Line 7: | ||
*[[Lung cancer after neoadjuvant therapy]]. | *[[Lung cancer after neoadjuvant therapy]]. | ||
*[[Residual cancer burden index]]. | *[[Residual cancer burden index]]. | ||
*[[Tumour regression]]. | |||
==References== | ==References== | ||
Latest revision as of 18:48, 5 May 2025
Neoadjuvant therapy is systemic treatment after diagnosis (on biopsy) prior to (definitive) local therapy.[1]
Post-neoadjuvant therapy and complete pathologic response redirect here.
See also
- Cancer drugs.
- Lung cancer after neoadjuvant therapy.
- Residual cancer burden index.
- Tumour regression.